English Overview
We are pleased to invite you to the webinar titled ‘New Evolution in the Management of Atopic Dermatitis’ presented by Prof. Kristian Reich.
This Activity for
- Resident / Fellow
- Physician
What I will learn?
Prof. Kristian Reich will discuss:
- why targeting JAK1/2 in atopic dermatitis improves atopic dermatitis skin signs and symptoms.
- what implications targeting JAK1/2 might have on safety signals.
- the importance of interpreting safety concerns as well as JAK selectivity in the context of the safety profile in clinical trials.
- what implication Baricitinib molecule characteristics beyond JAK inhibition have on clinical practice.
- why targeting JAK1/2 in atopic dermatitis improves atopic dermatitis skin signs and symptoms.
- what implications targeting JAK1/2 might have on safety signals.
- the importance of interpreting safety concerns as well as JAK selectivity in the context of the safety profile in clinical trials.
- what implication Baricitinib molecule characteristics beyond JAK inhibition have on clinical practice.
Instructors 1 Distinguished Speakers
Recorded Programs
New Evolution in The Management of Atopic Dermatitis Part 1
Due Date 05/05/2021
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
New Evolution in The Management of Atopic Dermatitis Certificate
Accreditation |
Certificate | Free |
VAT 15% Included
